Major Depressive Disorder Clinical Trials

95 studies are recruiting for major depressive disorder in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 4

1. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

   The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, …

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Autobahn Site #131, Birmingham, Alabama

   Locations

   50 in total

   Run by

   Autobahn Therapeutics, Inc.

   See if you can join NCT06633016 on ClinicalTrials.gov

2. Taking Action for College Students

   The goal of this research is to investigate whether a peer-delivered illness self-management program called Taking Action can help college students with serious mental illnesses. Participants will be randomly assigned to either the experimental condition (Taking Action) or the control condition (in…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Temple University, Philadelphia, Pennsylvania

   Run by

   Temple University

   See if you can join NCT06700902 on ClinicalTrials.gov

3. Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

   The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large sample of matched historical controls. Patients will be recruited from an…

   Stage

   Phase 4

   Ages

   18 to 70

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT05450432 on ClinicalTrials.gov

4. Psilocybin rTMS for Treatment Resistant Depression

   The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.

   Stage

   Phase 2

   Ages

   22 to 65

   Site

   Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas

   Run by

   University of Texas at Austin

   See if you can join NCT06132178 on ClinicalTrials.gov

5. Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

   The goal of this clinical trial is to learn how hormonal changes over the menstrual cycle affect mood symptoms in reproductive-aged women with depression that worsens during the premenstrual period. The main questions it aims to answer are: --How do fluctuations in estradiol and progesterone across…

   Stage

   Phase 4

   Ages

   18 to 45

   Site

   University of North Carolina, Chapel Hill, Chapel Hill, North Carolina

   Run by

   University of North Carolina, Chapel Hill

   See if you can join NCT06610305 on ClinicalTrials.gov

6. Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Little Rock, Arkansas

   Locations

   18 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06786624 on ClinicalTrials.gov

7. Stress Dynamics and Familial Risk for Depression in Female Adolescents

   Stress and a parental history of major depressive disorder (MDD) are among the strongest risk factors for future development of MDD. Studies have shown that having a parental history of MDD may be associated with behavioral, psychophysiological, and hormonal responses to stress that are associated …

   Stage

   Not phased

   Ages

   13 to 15

   Site

   McLean Hospital, Belmont, Massachusetts

   Run by

   Mclean Hospital

   See if you can join NCT06816329 on ClinicalTrials.gov

8. Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics

   The goal of this randomized controlled trial is to evaluate the potential of a customized digital cognitive training intervention to target aspects of brain function in apathy of late-life depression and reduce symptoms of apathy and related cognitive and behavioral deficits. The investigators hypo…

   Stage

   Not phased

   Ages

   60 and older

   Site

   AdventHealth Neuroscience Institute, Orlando, Florida

   Run by

   AdventHealth

   See if you can join NCT05877885 on ClinicalTrials.gov

9. Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression

   This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. I…

   Stage

   Not phased

   Ages

   18 to 45

   Site

   McLean Hospital, Belmont, Massachusetts

   Run by

   Mclean Hospital

   See if you can join NCT05630963 on ClinicalTrials.gov

10. Linking Affective Dynamics in Response to Daily Stress to Peripheral Vascular Function in Working Age Adults

    The objective of this proposal is to determine whether heightened negative affective responsivity (NA-R) to daily stressors is related to blunted nitric oxide (NO)-mediated endothelium-dependent dilation (EDD) in working age adults and the extent to which this association is impacted by major depre…

    Stage

    Not phased

    Ages

    18 to 55

    Site

    University of Delaware, Newark, Delaware

    Run by

    University of Delaware

    See if you can join NCT06860724 on ClinicalTrials.gov

11. Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

    This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications. Brain ima…

    Stage

    Phase 2

    Ages

    18 to 85

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05570812 on ClinicalTrials.gov

12. Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

    In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT04296604 on ClinicalTrials.gov

13. Mechanisms of Rumination Change in Adolescent Depression

    This study will evaluate whether a newer treatment, rumination-focused cognitive behavioral treatment, which includes mindfulness and can be used to reduce ruminative habits, change ways in which key brain regions interact with each other (e.g.., often called connectivity), and whether these change…

    Stage

    Not phased

    Ages

    14 to 17

    Site

    Nationwide Children's Hospital, Columbus, Ohio

    Locations

    3 in total

    Run by

    Ohio State University

    See if you can join NCT03859297 on ClinicalTrials.gov

14. Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression

    The proposed study is a single-site, randomized, controlled clinical trial (RCT) comparing ketamine-assisted psychotherapy (KAP) to a standard evidence-based regimen of ketamine administered in a medical model without psychotherapy (KET). Eligible study participants will be adults with major depres…

    Stage

    Phase 2

    Ages

    18 to 90

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT06559826 on ClinicalTrials.gov

15. Neural Circuit Effects of Ketamine in Depression

    This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT06213324 on ClinicalTrials.gov

16. Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

    This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at sev…

    Stage

    Phase 2

    Ages

    21 to 80

    Site

    Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT06592833 on ClinicalTrials.gov

17. A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Clinical Research Site, Bellflower, California

    Locations

    40 in total

    Run by

    Axsome Therapeutics, Inc.

    See if you can join NCT06223880 on ClinicalTrials.gov

18. Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder

    The purpose of this study is to examine the feasibility and acceptability of an online group Neuro-behavioral Therapy (NBT) with text messaging intervention for Veterans with epilepsy and major depressive disorder (MDD).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Michael E. DeBakey VA Medical Center, Houston, Texas

    Locations

    2 in total

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT06695767 on ClinicalTrials.gov

19. RIVER At Home Ketamine Protocols

    Multiple site studies with the recruitment of other sub-investigators and sites. It's sobering to consider how chronic illness makes us more vulnerable to suicidal thoughts and behavior. However, the existence of multiple risk factors also means that there are numerous ways to intervene. Addressing…

    Stage

    Not phased

    Ages

    18 and older

    Site

    RIVER Foundation, Bigfork, Montana

    Locations

    2 in total

    Run by

    RIVER Foundation

    See if you can join NCT06070766 on ClinicalTrials.gov

20. Peripheral Neuroimmune Mechanisms of Hyperthermia

    The goal of this study is to examine how whole-body hyperthermia affects the thermoinflammatory profile, which includes the combined immune and heat shock response, in patients with depression and whether these changes correlate with decreased depression in individuals with Major Depressive Disorde…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Massachusetts General Hospital Depression Clinical & Research Program, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05366270 on ClinicalTrials.gov